Next Article in Journal / Special Issue
Gas Vesicle Nanoparticles for Antigen Display
Previous Article in Journal
Small Wonders—The Use of Nanoparticles for Delivering Antigen
Previous Article in Special Issue
Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants
Review

Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy

by 1,2 and 1,2,3,*
1
Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA
2
Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA
3
Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Darrell J. Irvine
Vaccines 2015, 3(3), 662-685; https://doi.org/10.3390/vaccines3030662
Received: 17 July 2015 / Revised: 19 August 2015 / Accepted: 20 August 2015 / Published: 27 August 2015
(This article belongs to the Special Issue Nanoparticle-Based Vaccines)
Recent studies have demonstrated great therapeutic potential of educating and unleashing our own immune system for cancer treatment. However, there are still major challenges in cancer immunotherapy, including poor immunogenicity of cancer vaccines, off-target side effects of immunotherapeutics, as well as suboptimal outcomes of adoptive T cell transfer-based therapies. Nanomaterials with defined physico-biochemical properties are versatile drug delivery platforms that may address these key technical challenges facing cancer vaccines and immunotherapy. Nanoparticle systems have been shown to improve targeted delivery of tumor antigens and therapeutics against immune checkpoint molecules, amplify immune activation via the use of new stimuli-responsive or immunostimulatory materials, and augment the efficacy of adoptive cell therapies. Here, we review the current state-of-the-art in nanoparticle-based strategies designed to potentiate cancer immunotherapies, including cancer vaccines with subunit antigens (e.g., oncoproteins, mutated neo-antigens, DNA and mRNA antigens) and whole-cell tumor antigens, dendritic cell-based vaccines, artificial antigen-presenting cells, and immunotherapeutics based on immunogenic cell death, immune checkpoint blockade, and adoptive T-cell therapy. View Full-Text
Keywords: cancer immunotherapy; nanotechnology; cancer vaccine; lymphoid draining; adjuvant; dendritic cell; immune checkpoint; adoptive cell therapy cancer immunotherapy; nanotechnology; cancer vaccine; lymphoid draining; adjuvant; dendritic cell; immune checkpoint; adoptive cell therapy
Show Figures

Figure 1

MDPI and ACS Style

Fan, Y.; Moon, J.J. Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines 2015, 3, 662-685. https://doi.org/10.3390/vaccines3030662

AMA Style

Fan Y, Moon JJ. Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines. 2015; 3(3):662-685. https://doi.org/10.3390/vaccines3030662

Chicago/Turabian Style

Fan, Yuchen, and James J. Moon. 2015. "Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy" Vaccines 3, no. 3: 662-685. https://doi.org/10.3390/vaccines3030662

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop